Use of hepcidin as a regulator of iron homeostasis

Patent metadata

Field	Value
Publication number	US-9782453-B2
Application number	US-201514747926-A
Country	US
Kind code	B2
Filing date	Jun 23, 2015
Priority date	May 25, 2001
Publication date	Oct 10, 2017
Grant date	Oct 10, 2017

Abstract

The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.

First claim

The invention claimed is:

1. A method for reducing iron overload in a patient in need thereof, comprising administering to the patient a polypeptide comprising the sequence of
SEQ ID NO: 1.

2. A method according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

3. A method according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

4. A method according to claim 1 , wherein the patient has hemochromatosis.

5. A method according to claim 4 , wherein the patient has a disease resulting from hemochromatosis, wherein the disease is selected from the group consisting of hepatocarcinoma, cardiomyopathy, and diabetes.

6. A method according to claim 1 , wherein the patient has hepatocarcinoma, cardiomyopathy, and diabetes.

7. The method according to claim 4 , wherein the polypeptide comprises the amino acid sequence other of SEQ ID NO: 3.

8. The method according to claim 6 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

9. The method according to claim 4 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 3.

10. The method according to claim 6 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 3.

11. The method according to claim 1 , wherein the patient has secondary iron overload.

12. The method according to claim 1 , wherein the patient has hereditary or congenital anemia.

13. The method according to claim 12 , wherein the hereditary or congenital anemia is thalassemia.

14. The method according to claim 11 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 3.

15. The method according to claim 11 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

16. A method according to claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1.

17. A method according to claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 2.

18. A method according to claim 1 , wherein the patient has hemochromatosis.

19. A method according to claim 18 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 3.

20. The method of claim 1 , wherein the patient has hereditary hemochromatosis.

21. The method according to claim 20 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

22. The method according to claim 20 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

23. The method according to claim 20 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 3.

24. The method of claim 1 , wherein the patient has anemia.

25. The method according to claim 24 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

26. The method according to claim 24 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

27. The method according to claim 24 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 3.

28. The method of claim 1 , wherein the patient has thalassemia.

29. The method according to claim 28 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

30. The method according to claim 28 , wherein the polypeptide comprises of the amino acid sequence of SEQ ID NO: 3.

31. The method according to claim 28 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 3.

32. A method according to claim 20 , wherein the polypeptide is administered parenterally.

33. A method according to claim 32 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection.

34. A method according to claim 23 , wherein the polypeptide is administered parenterally.

35. A method according to claim 34 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection.

36. A method according to claim 24 , wherein the polypeptide is administered parenterally.

37. A method according to claim 36 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection.

38. A method according to claim 27 , wherein the polypeptide is administered parenterally.

39. A method according to claim 38 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection.

40. A method according to claim 28 , wherein the polypeptide is administered parenterally.

41. A method according to claim 40 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection.

42. A method according to claim 31 , wherein the polypeptide is administered parenterally.

43. A method according to claim 42 , wherein the polypeptide is administered by intramuscular, subcutaneous, intravenous, or intraperitoneal injection.

Assignees

• Inst Nat Sante Rech Med

Inventors

• Nicolas Gael
• Vaulont Sophie
• Kahn Axel

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title